MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-08-2026
Tilray Cost of Revenue 2011-2026 | TLRY
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Tilray
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 480 M | 512 M | 390 M | 309 M | 190 M | 28.9 M | 9.16 M | 9.97 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 512 M | 9.16 M | 241 M |
Quarterly Cost of Revenue Tilray
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 160 M | 152 M | - | 134 M | 150 M | 140 M | - | 139 M | 146 M | 133 M | - | 157 M | 101 M | 105 M | 209 M | 112 M | 122 M | 117 M | 239 M | 34.5 M | 94.2 M | 82.5 M | - | 41.2 M | - | 35.2 M | 33.6 M | 17.7 M | - | 6.98 M | 5.57 M | 3.91 M | - | 2.44 M | 2.28 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 239 M | 2.28 M | 95.6 M |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M |  USA |
 |
Alimera Sciences
ALIM
|
10.8 M | - | - | $ 142 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
6.21 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.19 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
8.98 M | - | 10.11 % | $ 58.2 M | USA |
 |
Canopy Growth Corporation
CGC
|
189 M | $ 1.1 | 2.84 % | $ 118 M |  Canada |
 |
Catalent
CTLT
|
3.43 B | - | - | $ 11.5 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | - | - | $ 2.06 B |  France |
 |
China Pharma Holdings
CPHI
|
6.51 M | $ 0.59 | 6.08 % | $ 10.3 M |  China |
 |
DURECT Corporation
DRRX
|
1.72 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
6.59 M | $ 3.81 | -16.81 % | $ 53.6 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
946 M | - | - | $ 28.9 M |  Irlanda |
 |
Evolus
EOLS
|
100 M | $ 5.68 | 37.53 % | $ 366 M | USA |
 |
Harrow Health
HROW
|
67.9 M | $ 40.02 | 3.65 % | $ 1.47 B | USA |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
Jupiter Wellness
JUPW
|
3.15 M | - | - | $ 33.6 M | USA |
 |
Emergent BioSolutions
EBS
|
705 M | $ 8.95 | 0.39 % | $ 458 M | USA |
 |
Assertio Holdings
ASRT
|
27 M | $ 12.19 | 2.48 % | $ 866 M | USA |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.4 | 2.19 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 2.87 | 0.01 % | $ 378 M | USA |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.55 | 1.21 % | $ 3.37 M | Canada |
 |
Perrigo Company plc
PRGO
|
2.76 B | $ 11.71 | 2.81 % | $ 1.62 B | USA |
 |
ProPhase Labs
PRPH
|
52 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
74.9 M | $ 0.91 | 1.03 % | $ 21.2 M | USA |
 |
Pacira BioSciences
PCRX
|
170 M | $ 22.92 | 3.69 % | $ 1.06 B | USA |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
8.63 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 4.79 | 2.57 % | $ 144 M | USA |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 0.76 | 1.22 % | $ 36.4 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
8.82 M | $ 2.74 | -0.36 % | $ 3.4 M | USA |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 2.25 | 1.35 % | $ 23.5 M | USA |
 |
Veru
VERU
|
11 M | $ 2.53 | 0.4 % | $ 341 M | USA |
 |
Viatris
VTRS
|
8.99 B | $ 14.74 | -1.04 % | $ 17.7 B | USA |
 |
cbdMD
YCBD
|
7.49 M | $ 0.75 | -2.76 % | $ 3.23 M | USA |